Enterprise Value
9.516M
Cash
19.31M
Avg Qtr Burn
-9.03M
Short % of Float
0.05%
Insider Ownership
61.26%
Institutional Own.
0.77%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Ryplazim® (plasminogen) Details Congenital Plasminogen Deficiency (C-PLGD) | Approved Quarterly sales | |
LMNL6511 (GPR84 receptor) Details Non-alcoholic steatohepatitis , Metabolic disorder, Non-Alcoholic Fatty Liver Disease, Idiopathic pulmonary fibrosis | Phase 1 Initiation | |
Fezagepras (PBI-4050) Details Triglycerides | Failed Discontinued | |
Fezagepras (PBI-4050) Details Rare diseases, Lung disease | Failed Discontinued | |
Fezagepras (PBI-4050) Details Rare diseases, Rare genetic disease | Failed Discontinued |